
New abstracts show the oral PCSK9 inhibitor cut LDL-C by 57% to 63% across PREVENT risk groups, with reductions maintained in an extension study.
The American Journal of Managed Care
over 18 years ago
Information for Authorsover 18 years ago
Financial Incentives for Quality in Breast Cancer Care





